Rivaroxaban exhibits food-dependent, dissolution-limited absorption in the stomach and proximal small intestine, and systemic exposure appears more sensitive to residual bowel length. Apixaban demonstrates linear, food-independent pharmacokinetics and generally preserved absorption in stable SBS, enabling concentration-guided dose adjustment when needed. Both agents can be effective in selected patients, but apixaban offers greater pharmacokinetic robustness in the context of altered intestinal anatomy or inconsistent oral intake. Early anti-Xa - based monitoring is advisable for either drug to confirm adequate absorption.
Hronová et al. (Fri,) studied this question.